Psg22 Inhibitors
Psg22 inhibitors are a class of small molecules or compounds that target and inhibit the activity of the PSG22 protein, a member of the pregnancy-specific glycoprotein (PSG) family. These glycoproteins are part of the immunoglobulin superfamily, which are typically involved in cellular interactions, adhesion, and signaling pathways within the immune system and other physiological processes. PSG22 is of interest due to its specific structure and role in biological signaling, where its modulation can affect various pathways, particularly those associated with cell signaling and interactions. The design of Psg22 inhibitors focuses on understanding the protein's three-dimensional conformation and the active sites crucial for its function. By binding to these active regions, these inhibitors prevent the normal activity of PSG22, thereby modulating downstream signaling pathways in cellular environments.
The chemical nature of Psg22 inhibitors varies, encompassing a diverse range of molecular scaffolds, functional groups, and binding affinities. They are often designed to have a high specificity and affinity for PSG22 to ensure effective inhibition with minimal off-target interactions. The chemical properties, such as lipophilicity, charge distribution, and size, are carefully optimized to enhance their binding efficiency and bioavailability. The development of Psg22 inhibitors often involves high-throughput screening of compound libraries, followed by structure-activity relationship (SAR) studies to refine and improve inhibitory potency and selectivity. Such inhibitors are valuable tools in biochemical and cellular research for studying the role of PSG22 and its associated pathways. Understanding the structure and function of these molecules provides insight into the physiological roles of PSG22 and advances the fundamental knowledge of its biological impact within cellular systems.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin gallate (EGCG) is a known inhibitor of several signaling pathways, including those involved in inflammation and oxidative stress. As Psg22 might be implicated in these processes, EGCG could inhibit Psg22 by attenuating the signaling pathways that facilitate its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of the PI3K/Akt pathway, which is involved in cell survival and proliferation. If Psg22 activity is linked to these cellular processes, inhibition of PI3K/Akt by LY294002 would lead to a decrease in Psg22 activity as a downstream effect. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of the MEK/ERK pathway, which is involved in cell growth and differentiation. Psg22, if involved in these processes, could be functionally inhibited as a downstream consequence of blocking the MEK/ERK signaling cascade. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase, a protein involved in response to stress and inflammation. If Psg22 operates within this pathway, inhibition of p38 MAP kinase could result in reduced Psg22 activity due to decreased signaling through this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK signaling, which is implicated in apoptosis and cellular stress responses. Inhibition of JNK could lead to lower Psg22 activity if Psg22 is part of the JNK signaling pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, key components of the ERK pathway. By inhibiting MEK1/2, U0126 could reduce Psg22 activity if Psg22 function is dependent on the ERK signaling pathway. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
ZM-447439 is an Aurora kinase inhibitor. Aurora kinases play a role in mitotic progression, and if Psg22 is involved in cell division, inhibiting these kinases could indirectly inhibit Psg22 by disrupting the processes in which it is involved. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is an inhibitor of phosphoinositide 3-kinases (PI3K), which are involved in a variety of cellular functions including cell growth and survival. Since Psg22 could be associated with these processes, inhibition of PI3K by wortmannin could result in decreased Psg22 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, and mTOR is a central component of cell growth and metabolism regulation. If Psg22 is involved in pathways regulated by mTOR, rapamycin could functionally inhibit Psg22 activity by disrupting mTOR signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src kinase inhibitor, and Src kinases are involved in various signal transduction pathways. If Psg22 is associated with pathways that involve Src kinase activity, dasatinib could reduce Psg22 activity by inhibiting Src kinases. | ||||||